探索司美格鲁肽片在T2DM管理中的作用

*仅供医学专业人士阅读参考

专家简介

高妍教授

北京大学第一医院

• 北京大学第一医院内分泌内科主任医师，教授，博士生导师
• 曾任北京大学第一医院内科副主任，内分泌科主任，检验科主任
• 主要从事内分泌内科的医疗，教学工作以及有关甲状腺疾病和糖尿病的临床研究和实验室研究工作
• 曾担任中华医学会内分泌分会副主任委员
• 现任中华医学会内分泌分会顾问
• 任《中华内科杂志》、《中华内分泌代谢杂志》等多家杂志编委
• 已培养出和正在培养多名硕士研究生和博士研究生，已有不少在国内内分泌领域成为学科带头人
• 曾获中华医学会糖尿病学会以及内分泌学会终身成就奖

参考文献：

[1]Aroda,V.R.,et al.,PIONEER 1:Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.Diabetes Care,2019.42(9):p.1724-1732.

[2]Rodbard,H.W.,et al.,Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin:The PIONEER 2 Trial.Diabetes Care,2019.42(12):p.2272-2281.

[3]Rosenstock,J.,et al.,Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea:The PIONEER 3 Randomized Clinical Trial.JAMA,2019.321(15):p.1466-1480.

[4]Pieber,T.R.,et al.,Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes(PIONEER 7):a multicentre,open-label,randomised,phase 3a trial.Lancet Diabetes Endocrinol,2019.7(7):p.528-539.

[5]Pratley,R.,et al.,Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes(PIONEER 4):a randomised,double-blind,phase 3a trial.Lancet,2019.394(10192):p.39-50.

[6]Zinman,B.,et al.,Efficacy,Safety,and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes:The PIONEER 8 Trial.Diabetes Care,2019.42(12):p.2262-2271.

[7]Afkarian,M.,et al.,Clinical Manifestations of Kidney Disease Among US Adults With Diabetes,1988-2014.JAMA,2016.316(6):p.602-10.

[8]de Boer,I.H.,et al.,Temporal trends in the prevalence of diabetic kidney disease in the United States.JAMA,2011.305(24):p.2532-9.

[9]Zhang,X.X.,J.Kong,and K.Yun,Prevalence of Diabetic Nephropathy among Patients with Type 2 Diabetes Mellitus in China:A Meta-Analysis of Observational Studies.J Diabetes Res,2020.2020:p.2315607.

[10]Mosenzon,O.,et al.,Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment(PIONEER 5):a placebo-controlled,randomised,phase 3a trial.Lancet Diabetes Endocrinol,2019.7(7):p.515-527.

[11]Husain,M.,et al.,Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N Engl J Med,2019.381(9):p.841-851.

[12]Husain,M.,M.Donsmark,and S.C.Bain,Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes.Reply.N Engl J Med,2019.381(21):p.2076-2077.

[13]Yamada,Y.,et al.,Dose-response,efficacy,and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes(PIONEER 9):a 52-week,phase 2/3a,randomised,controlled trial.Lancet Diabetes Endocrinol,2020.8(5):p.377-391.

[14]Yabe,D.,et al.,Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes(PIONEER 10):an open-label,randomised,active-controlled,phase 3a trial.Lancet Diabetes Endocrinol,2020.8(5):p.392-406.

“此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场”